{
  "id": "601dbeb31cb411341a00004e",
  "type": "list",
  "question": "Please list 3 biologic(monoclonal antibody) drugs used to treat migraine headaches.",
  "ideal_answer": " Large molecule biologic antibody (mAb) approaches that are given subcutaneously to neutralize circulating CGRP peptide (fremanezumab, galcanezumab) or block CGRP receptors (erenumab) have shown consistent efficacy and tolerability in multicenter migraine prevention trials and are now approved for clinical use.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31122188",
    "http://www.ncbi.nlm.nih.gov/pubmed/28240610",
    "http://www.ncbi.nlm.nih.gov/pubmed/33363597",
    "http://www.ncbi.nlm.nih.gov/pubmed/33856626",
    "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
    "http://www.ncbi.nlm.nih.gov/pubmed/32145209",
    "http://www.ncbi.nlm.nih.gov/pubmed/29722276",
    "http://www.ncbi.nlm.nih.gov/pubmed/33542885",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/34246226",
    "http://www.ncbi.nlm.nih.gov/pubmed/33765912",
    "http://www.ncbi.nlm.nih.gov/pubmed/26879279",
    "http://www.ncbi.nlm.nih.gov/pubmed/26432182",
    "http://www.ncbi.nlm.nih.gov/pubmed/34742252",
    "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
    "http://www.ncbi.nlm.nih.gov/pubmed/31985655",
    "http://www.ncbi.nlm.nih.gov/pubmed/33023473",
    "http://www.ncbi.nlm.nih.gov/pubmed/30106172",
    "http://www.ncbi.nlm.nih.gov/pubmed/31020659",
    "http://www.ncbi.nlm.nih.gov/pubmed/33892641",
    "http://www.ncbi.nlm.nih.gov/pubmed/31050694",
    "http://www.ncbi.nlm.nih.gov/pubmed/29171818",
    "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
    "http://www.ncbi.nlm.nih.gov/pubmed/34115380",
    "http://www.ncbi.nlm.nih.gov/pubmed/34363708",
    "http://www.ncbi.nlm.nih.gov/pubmed/30886915",
    "http://www.ncbi.nlm.nih.gov/pubmed/34544359"
  ],
  "snippets": [
    {
      "text": " Large molecule biologic antibody (mAb) approaches that are given subcutaneously to neutralize circulating CGRP peptide (fremanezumab, galcanezumab) or block CGRP receptors (erenumab) have shown consistent efficacy and tolerability in multicenter migraine prevention trials and are now approved for clinical use.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31020659",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since 2004, mAbs have been used to treat several neurological diseases, yielding new therapeutic perspectives: natalizumab, alemtuzumab and ocrelizumab for multiple sclerosis, eculizumab for myasthenia gravis, erenumab and frenazumab for migraine, galcanezumab for migraine and cluster headache, eculizumab for neuromyelitis optica spectrum disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33363597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Erenumab, a first-in-class monoclonal antibody targeting the calcitonin gene-related peptide pathway, was approved by the US Food and Drug Administration in 2018 for the prevention of migraine in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33856626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26432182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "abotulinumtoxinA (BoNT-A) has become a very popular medication for treating migraine headaches in those cases in which other medication is not working, typically in chronic migraines. Cur",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " per year. OnabotulinumtoxinA (botulinum toxin type A) is a U.S. Food and Drug Administration-approved prophylactic medication for chronic migraine headaches and is best injected in a targeted fashion into specific trig",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31985655",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On September 15, 2018, the U.S. Food and Drug Administration (FDA) approved subcutaneous fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody, for the treatment of episodic and chronic migraine in adults, with two recommended dosages: 225 mg monthly or 675 mg every 3 months. On March",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050694",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of mig",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34544359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) and OnabotulinumtoxinA (botox) are used in the prevention of chronic migraines. Howe",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33542885",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objective - To evaluate 12-week changes from baseline of 2 disease-specific patient-reported outcome (PRO) measures in adults with migraine treated with galcanezumab, an investigational humanized antibody binding calcitonin gene-related peptide (CGRP), or placebo. Bac",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30106172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eceptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. As these d",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and chronic migrai",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29722276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "2018;38:1442-1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31122188",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34742252",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE OF REVIEW: The results of phase 2 randomized controlled trials for the prevention of episodic and chronic migraine demonstrating the efficacy and safety of four mAbs targeting the calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab), AMG334 (erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab)] have been published recently, and phase 3 tri",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28240610",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment f",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33765912",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33892641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (\u22646-month of treatment) a reduction in the number of migraine headache days and improved patients' ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody (IgG2\u0394a) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34246226",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "h migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention.METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26879279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and chronic migraine (CM).OBJECTIVE: Post-hoc analyses evaluated population-wise 50%, 75% and 100% responder rates, and the extent to which individual responders sustained a 50%, 75% and 100% reduction in migraine days, moderate-to-severe (M/S) headache days and days of acute medication use during all three treatment months of the fremanezumab phase 2 studies.DESIGN/METHODS: HFEM patients received either placebo or three once-monthly injections of 225\u2009mg or 675\u2009mg. CM patients received either placebo or three once-monthly injections of 900\u2009mg, or an initial loading dose of 675\u2009",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29722276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate the impact of fremanezumab on the severity and duration of remaining migraine attacks in patients with chronic migraine (CM) or episodic migraine (EM).BACKGROUND: Fremanezumab is a fully humanized monoclonal antibody (IgG\u0394a) that selectively targets calcitonin gene-related peptide and is efficacious in reducing migraine frequency.METHODS: This exploratory post hoc analysis included data from three randomized, double-blind, 12-week, phase 3 studie",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34115380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Food and Drug Administration (FDA) recently approved 3 new humanized monoclonal antibodies that target calcitonin gene-related peptide (CGRP): erenumab, fremanezumab, and galcanezumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32145209",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide-targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with chron",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34363708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The agents either bind to the CGRP receptor (erenumab) or bind to the CGRP ligand (fremanezumab and galcanezumab) and block its binding to the receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32145209",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "fremanezumab, galcanezumab, erenumab, aimovig, Eptinezumab"
}